By Jeff Overley (February 15, 2019, 6:41 PM EST) -- One of the Trump administration's boldest moves to ease drug prices — a ban on billions of dollars in rebates negotiated by middlemen for health insurers — will need to traverse a legal minefield to become reality, experts say.
The recent proposal would use threats of prison time and massive fines under the Anti-Kickback Statute to eliminate rebates negotiated in Medicare and Medicaid by pharmacy benefit managers, or PBMs. Rebates in those two programs — long shielded by an Anti-Kickback Statute safe harbor — total tens of billions of dollars annually.
"It's an amazing regulation in that ... it basically criminalizes the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!